Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This paper argues that androgenetic alopecia in transgender and gender-diverse individuals is clinically significant, suggesting individualized and gender-affirming treatment approaches, with oral minoxidil as a key therapy.

This article highlights that in Australia, transgender and gender-diverse patients experience specific dermatological challenges during gender-affirming treatments, such as acne and patterned hair loss. It emphasizes the need for tailored dermatological care and guidance for these patients.

This study reported that Tianma Gouteng decoction improved hair follicle regeneration in mice and identified its potential mechanism, primarily involving the Wnt/β-catenin signaling pathway, through a combination of network pharmacology, molecular docking, and experimental validation.

This study found that transgender and gender diverse patients on masculinizing hormone therapy had 2.5 times the rate of androgenetic alopecia compared to cisgender women.

In this study of transgender and gender-diverse adults, the researchers observed that one-third of those on psychotropic medications within two years of starting hormone therapy experienced psychotropic polypharmacy, with a significantly higher likelihood of potential drug-hormone interactions in this group.